A Russell Moore1, Adam Harris1, Christina Jeffries1, Paul R Avery1, Kate Vickery2. 1. Department of Microbiology, Immunology and Pathology, Colorado State University, Ft. Collins, Colorado, USA. 2. Department of Clinical Sciences, Colorado State University, Ft. Collins, Colorado, USA.
Abstract
BACKGROUND: Current recommendations for monitoring disease progression and response to treatment in humans with multiple myeloma include evaluation of serum paraprotein (M-protein) concentration. Densitometry, species-specific radial immunodiffusion (RID) and ELISA methods can be used to quantify M-proteins. OBJECTIVE: Retrospectively evaluate use of the International Myeloma Working Group (IMWG) response criteria for humans in dogs with multiple myeloma. ANIMALS: Sixteen dogs with a diagnosis of multiple myeloma, M-protein documented by serum protein electrophoresis (SPE) and immunofixation (IF) in an initial sample and subsequent electrophoretic evaluation of serial samples. METHODS: Retrospectively, densitometric M-proteins, RID and globulins were measured and characterized according to IMWG criteria. Available clinical history was reviewed. Overall survival time (OST) was calculated from initial electrophoretic evaluation to death or last contact. RESULTS: All cases received some form of nonstandardized chemotherapy. Complete response (CR), a lack of detectable M-protein by SPE and IF, was documented in 1 case. Median survival was longer for dogs that attained ≥90% densitometric M-protein reduction (630 days) than for those that did not attain at least 50% reduction in densitometric M-protein (284 days; log rank P = .006). Five dogs were defined as having progressive disease (M-protein increase of >25% and at least 0.5 g/dL from nadir), which correlated with concurrent or subsequent clinical deterioration. Response criteria categorized by serum globulins or RID was not correlated with OST or clinical findings. CONCLUSIONS AND CLINICAL IMPORTANCE: Densitometric M-protein characterized using IMWG response criteria correlated with OST and clinical findings. Densitometric M-protein detection should be used to monitor dogs with multiple myeloma.
BACKGROUND: Current recommendations for monitoring disease progression and response to treatment in humans with multiple myeloma include evaluation of serum paraprotein (M-protein) concentration. Densitometry, species-specific radial immunodiffusion (RID) and ELISA methods can be used to quantify M-proteins. OBJECTIVE: Retrospectively evaluate use of the International Myeloma Working Group (IMWG) response criteria for humans in dogs with multiple myeloma. ANIMALS: Sixteen dogs with a diagnosis of multiple myeloma, M-protein documented by serum protein electrophoresis (SPE) and immunofixation (IF) in an initial sample and subsequent electrophoretic evaluation of serial samples. METHODS: Retrospectively, densitometric M-proteins, RID and globulins were measured and characterized according to IMWG criteria. Available clinical history was reviewed. Overall survival time (OST) was calculated from initial electrophoretic evaluation to death or last contact. RESULTS: All cases received some form of nonstandardized chemotherapy. Complete response (CR), a lack of detectable M-protein by SPE and IF, was documented in 1 case. Median survival was longer for dogs that attained ≥90% densitometric M-protein reduction (630 days) than for those that did not attain at least 50% reduction in densitometric M-protein (284 days; log rank P = .006). Five dogs were defined as having progressive disease (M-protein increase of >25% and at least 0.5 g/dL from nadir), which correlated with concurrent or subsequent clinical deterioration. Response criteria categorized by serum globulins or RID was not correlated with OST or clinical findings. CONCLUSIONS AND CLINICAL IMPORTANCE: Densitometric M-protein characterized using IMWG response criteria correlated with OST and clinical findings. Densitometric M-protein detection should be used to monitor dogs with multiple myeloma.
Authors: Ronald A Booth; Christopher R McCudden; Cynthia M Balion; Ivan M Blasutig; Ihssan Bouhtiauy; Karina Rodriguez-Capote; Peter Catomeris; Pak Cheung Chan; Yu Chen; Christine Collier; Kristin Hauff; Jawahar Kalra; Dailin Li; Dan C Lin; Amy H Lou; Qing H Meng; Tracy Morrison; Maria D Pasic; Mabood Qureshi; Ed Randell; Kun-Young Sohn; Vinita Thakur; Dylan Thomas; Andrea Thoni; Cheryl Tomalty; Liju Yang; Mohebullah Zamkanei Journal: Clin Biochem Date: 2017-10-20 Impact factor: 3.281
Authors: A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie Journal: Leukemia Date: 2008-11-20 Impact factor: 11.528
Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316
Authors: Paul J Mellor; Sean Haugland; Sue Murphy; Ken C Smith; Andrew Holloway; Joy Archer; Roger M Powell; Gerry A Polton; Severine Tasker; David McCormick; Michelle E Tempest; Pauline E McNeil; Timothy J Scase; Chris D Knott; Ugo Bonfanti; Elizabeth J Villiers; David J Argyle; Michael E Herrtage; Michael J Day Journal: J Vet Intern Med Date: 2006 Nov-Dec Impact factor: 3.333
Authors: Amy K LeBlanc; Christina N Mazcko; Timothy M Fan; David M Vail; Brian K Flesner; Jeffrey N Bryan; Shan Li; Feng Wang; Scott Harris; Jesse D Vargas; Jeevan P Govindharajulu; Soumya Jaganathan; Francesca Tomaino; Apurva K Srivastava; Tsui-Fen Chou; Gordon M Stott; Joseph M Covey; Barbara Mroczkowski; James H Doroshow Journal: Mol Cancer Ther Date: 2022-10-07 Impact factor: 6.009
Authors: Robert Adam Harris; Matthew Miller; Dillon Donaghy; Laura Ashton; Catherine Langston; Todd Shockey; A Russell Moore Journal: J Vet Intern Med Date: 2021-02-26 Impact factor: 3.333